InRange webinar bytes 3: Primary and safety results by Dr. Tadej Battelino and Dr. Eric Renard

Long-term micro and macrovascular damages are linked to suboptimal glycemic control and glycemic variability. InRange study is one of the first studies to use continuous glucose monitoring metrics as the primary endpoint to compare second-generation basal insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in persons with type 1 diabetes. Watch Dr. Taddej Battelino and E. Renard discussing the results of this trial.